drugset / Trial / NCT01325441
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
Timeline
- Start
- 2011-04
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Napabucasin | Small molecule | 200 mg | Oral |
| Subject | Napabucasin | Small molecule | 240 mg | Oral |
| Subject | Napabucasin | Small molecule | 400 mg | Oral |
| Subject | Napabucasin | Small molecule | 480 mg | Oral |
| Subject | Napabucasin | Small molecule | 500 mg | Oral |
| Background | Paclitaxel | Small molecule | — | — |